AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
Johnson & Johnson’s Janssen Supply Group is to be the first tenant in Fujifilm Diosynth Biotechnologies’ $2 billion cell culture manufacturing facility, which is planned to open in Holly Springs, North Carolina, in 2025.
The Chinese contract research, development and manufacturing organization (CRDMO) WuXi XDC has launched a bid to raise up to HK$3.7 billion (US$470.3 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).
The antibody drug nipocalimab, developed by the Janssen Pharmaceutical...
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.
The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.
Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.
The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for...
Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).
Scarlet Therapeutics, a leader in red blood cell-based therapeutics, has raised seed funding from Science Creates Ventures and Meltwind to develop its platform and build a pipeline of novel therapies.
The US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate (ADC) later this year.
CDMO Sterling Pharma Solutions has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
As part of a $1 billion deal forged in 2020, Biogen has exercised the option to license a treatment candidate for Alzheimer’s disease developed by the US biotech company Denali Therapeutics. The engineered antibody drug is designed to cross into the brain...
Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...
The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...
BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.
The US biotech CytomX has lost a collaboration partner as AbbVie pulled out of a collaboration developing an antibody-drug conjugate (ADC) for the treatment of solid tumours.
In acquiring antibody-drug conjugates technology pioneer Seagen, Pfizer eyes up the strong growth trajectories of Seagen's medicines and the potential of its pipeline and technology.
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.
The South Korean player plans to expand its recently acquired US facility, to provide contract manufacturing services for Antibody Drug Conjugates (ADC), and to add drug product fill & finish facilities to establish a foothold in the North American...
There has been a flurry of antibody-drug conjugate (ADC) agreements in recent weeks, and today sees the inking of another deal involving Tokyo headquartered Ajinomoto Co Inc and US biotech, Exelixis.
Moderna and CytomX Therapeutics have announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies using Moderna's mRNA technologies and CytomX's Probody therapeutic platform.
Pyxis Oncology has received clearance for two IND applications from the US Food and Drug Administration (FDA) to initiate two Phase 1 clinical studies.
NextCure and LegoChem Biosciences have announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
IGM Biosciences is teaming up with ADC Therapeutics on a clinical trial collaboration and supply agreement to assess the combination of an IgM antibody and an ADC for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma...
Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.
Biomanufacturing company National Resilience has announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.
The antibody drug conjugate market has had a busy few years, as the appetite for acquisitions of ADC-specialists began to grow, with Gilead buying Immunomedics and Merck acquiring VelosBio.
Merck has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin, US.
Capital investments in Swiss biotech companies reached CHF 3.33bn ($3.53bn) in 2021; while R&D investments increased to a record-high CHF 2.56bn ($2.71bn).
Bionova Scientific, a US biologics CDMO, is to be acquired by the US arm of Asahi Kasei Medical, part of the Asahi Kasei Group, owned by Tokyo based Asahi Kasei Corporation.
Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.
While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...
CDMO Piramal Pharma Solutions will expand capabilities of its Antibody-Drug Conjugate (ADC) facility in Grangemouth, Scotland; and invest in new Active Pharmaceutical Ingredient (API) infrastructure at its Morpeth, England facility.
Indian multinational, Piramal Pharma Limited (PPL), has taken a minority stake in Yapan Bio, a CDMO, based in Hyderabad, with expertise in biologics and vaccines.
This month saw BioCina officially open its new biologics manufacturing facility in Adelaide, Australia, flagging it as the only TGA, EMA, Health Canada and US-FDA approved commercial facility of its kind in the country.
